Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model

Using a novel orthotopic MBT-2 murine bladder tumor model, we evaluated the feasibility of intravesical gene therapy utilizing a cationic liposome, DMRIE/DOPE. Superficial bladder tumors were consistently established by intravesical instillation of 5 × 105MBT-2 cells in syngeneic C3H female mice. In situ gene transfer to bladder tumors was accomplished via intravesical instillation of plasmid DNA/DMRIE/DOPE lipoplex. β-Galactosidase (β-gal) gene expression was preferentially evident in bladder tumors and was present for at least 7 days after a single 30 min in situ transfection. Murine interleukin-2 (IL-2) gene was used for treatment of 3-day-old pre-established bladder tumors. Forty percent of animals treated with IL-2 gene were completely free of tumors by 60 days following the initial tumor implantation, while all control groups treated with β-gal gene died. Those animals initially cured of pre-established tumors were completely resistant to a subsequent tumor re-challenge and their splenocyte-derived cytotoxic T lymphocytes were shown to be specific to MBT-2 cells, indicating that immunological memory against MBT-2 tumors was elicited by the treatment. These results demonstrate the possibility of an effective clinical application of this in situ intravesical IL-2 gene delivery system to high-risk superficial bladder tumors, obviating a need for tumor procurement and ex vivo gene transfer.

[1]  M. Brenner,et al.  High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors. , 1996, Human gene therapy.

[2]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  E. Sabo,et al.  Treatment of experimental mouse bladder tumour by LPS-induced epithelial cell shedding. , 1996, British Journal of Cancer.

[4]  T. Boon,et al.  Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[5]  I. Fidler,et al.  Critical factors in the biology of human cancer metastasis. , 1995, The American surgeon.

[6]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[7]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[8]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[9]  J. Marshall,et al.  Improved Cationic Lipid Formulations for In Vivo Gene Therapy , 1995, Annals of the New York Academy of Sciences.

[10]  K. Barnhart,et al.  Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity. , 1998, Cancer gene therapy.

[11]  D. Curiel,et al.  Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. , 1995, Cancer gene therapy.

[12]  K. Harimoto,et al.  In vivo gene transfer methods in the bladder without viral vectors. , 1998, British journal of urology.

[13]  E. Gilboa,et al.  Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. , 1994, Cancer research.

[14]  W. Catalona,et al.  Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin. , 1984, Cancer research.

[15]  K. Drazan,et al.  Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. , 1996, The Journal of urology.

[16]  A. Stopeck,et al.  Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. , 1996, Cancer gene therapy.

[17]  E. Nabel,et al.  Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Engler,et al.  Enhanced Adenovirus-Mediated Gene Transfer To The Urothelium For Gene Therapy Of Transitional Cell Carcinoma , 1999 .

[19]  F. Sorgi,et al.  In vivo cytokine gene therapy of human tumor xenografts in SCID mice by liposome-mediated DNA delivery. , 1996, Gene therapy.

[20]  E. Gilboa,et al.  Anti‐metastatic vaccination of tumor‐bearing mice with il‐2‐gene‐inserted tumor cells , 1993, International journal of cancer.

[21]  E. Gilboa,et al.  Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  F. Marshall,et al.  High efficiency gene transfer into primary human tumor explants without cell selection. , 1993, Cancer research.

[23]  M. Soloway,et al.  Experimental chemotherapy of bladder cancer--systemic and intravesical. , 1979, Seminars in oncology.

[24]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[25]  S. Durham,et al.  Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis , 1995, Nature Medicine.

[26]  R. Connor,et al.  Ethanol improves adenovirus-mediated gene transfer and expression to the bladder epithelium of rodents. , 1999, Urology.

[27]  E. Gilboa,et al.  Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. , 1993, Journal of immunology.

[28]  E. Gilboa,et al.  Regression of bladder tumors in mice treated with interleukin 2 gene- modified tumor cells [published erratum appears in J Exp Med 1993 Jun 1;177(6):following 1831] , 1993, The Journal of experimental medicine.

[29]  K. Barnhart,et al.  An improved plasmid DNA expression vector for direct injection into skeletal muscle. , 1996, Human gene therapy.

[30]  P. Felgner.  Improvements in cationic liposomes for in vivo gene transfer. , 1996, Human gene therapy.

[31]  W. Catalona,et al.  Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. , 1987, The Journal of urology.

[32]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[33]  L. Eisenlohr,et al.  Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. , 1994, Cancer research.

[34]  W. Catalona,et al.  T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. , 1993, The Journal of urology.

[35]  E. Nabel,et al.  A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. , 1996, Human gene therapy.

[36]  J. Richie,et al.  Biology and management of bladder cancer. , 1990, The New England journal of medicine.

[37]  R. Scheule,et al.  Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. , 1996, Human gene therapy.

[38]  D. Pardoll,et al.  Limitations of adenovirus‐mediated interleukin‐2 gene therapy for oral cancer , 1999, The Laryngoscope.